LOS ANGELES, Calif.--(BUSINESS WIRE)--Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company,
today announced that the U.S. Food and Drug Administration (FDA) has
scheduled the New Drug Application (NDA) for neratinib for discussion by
the Oncologic Drugs Advisory Committee (ODAC) on May 24, 2017. Neratinib
is an investigational therapy for the extended adjuvant treatment of
early stage HER2-positive breast cancer that has previously been treated
with a trastuzumabmore...